dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse

This website has run out of funding so feel free to contribute if you can afford it (see footer)

Author Topic: Glutamate Unlocks Brain Cell Channels to Enable Thinking and Learning (Molecular  (Read 572 times)

Offline smfadmin (OP)

  • SMF (internal) Site
  • Administrator
  • Full Member
  • *****
  • Join Date: Dec 2014
  • Location: Management
  • Posts: 369
  • Reputation Power: 0
  • smfadmin has hidden their reputation power
  • Last Login:April 17, 2025, 07:45:30 PM
  • Supplied Install Member
https://neurosciencenews.com/glutamate-ampa-learning-memory-28523/

March 31, 2025

'α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid', better known as AMPA, is a compound that is a specific agonist for the AMPA receptor, where it mimics the effects of the neurotransmitter glutamate

... see AMPAWiki

Summary:

Researchers used advanced cryo-electron microscopy to capture atomic-level images of how glutamate, a key neurotransmitter, opens channels in brain cells.

These channels, known as AMPA receptors, are essential for neuron-to-neuron communication and play a role in learning, memory, and disorders like epilepsy.

The study showed that glutamate acts like a key, triggering a clamshell-like motion in the receptor that opens the channel to allow charged particles to flow. This breakthrough provides critical insights that could guide the development of drugs to modulate brain signaling in various neurological conditions.

Key Facts:

● Molecular Mechanism: Glutamate opens AMPA receptors by triggering a clamshell closure that unlocks the channel.

● Imaging Breakthrough: Over a million cryo-EM images captured receptor dynamics at atomic resolution.

● Therapeutic Insight: Findings could support drug design for epilepsy and cognitive disorders.

In an effort to understand how brain cells exchange chemical messages, scientists say they have successfully used a highly specialized microscope to capture more precise details of how one of the most common signaling molecules, glutamate, opens a channel and allows a flood of charged particles to enter.

The finding, which resulted from a study led by Johns Hopkins Medicine researchers, could advance the development of new drugs that block or open such signaling channels to treat conditions as varied as epilepsy and some intellectual disorders.

A report on the experiments, funded by the National Institutes of Health and in collaboration with scientists at UTHealth Houston, was published March 26 in the journal Nature.

“Neurons are the cellular foundation of the brain, and the ability to experience our environment and learn depends on [chemical] communications between neurons,” says Edward Twomey, Ph.D., assistant professor of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine.

Scientists have long known that a major molecule responsible for neuron-to-neuron communications is the neurotransmitter glutamate, a molecule abundant in the spaces between neurons.

Its landing place on neurons is a channel called an AMPA receptor, which interacts with glutamate, and then acts like a pore that takes in charged particles.

The ebb and flow of charged particles creates electrical signals that form communications between neurons.

“Neurons are the cellular foundation of the brain, and the ability to experience our environment and learn depends on [chemical] communications between neurons,” says Edward Twomey, Ph.D., assistant professor of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine.

Scientists have long known that a major molecule responsible for neuron-to-neuron communications is the neurotransmitter glutamate, a molecule abundant in the spaces between neurons.

Its landing place on neurons is a channel called an AMPA receptor, which interacts with glutamate, and then acts like a pore that takes in charged particles. The ebb and flow of charged particles creates electrical signals that form communications between neurons.

To figure out details of the miniscule movements of AMPA receptors (at the level of single atoms), researchers used a very high-powered microscope to image these channels during specific steps in the communications processes. For the study, the scientists used a cryo-electron microscope (cryo-EM) in a facility at the Johns Hopkins University School of Medicine.

Typically, scientists find it easier to study cell samples that are chilled, a state that provides a stable environment. But at normal body temperature, Twomey’s team found that the AMPA receptors and glutamate activity increased, providing more opportunities to capture this process in cryoEM images.

To that end, the scientists purified AMPA receptors, taken from lab-grown human embryonic cells that are used widely in neuroscience research to produce such proteins. Then, they heated the receptors to body temperature (37 degrees Celsius or 98.6 degrees Fahrenheit) before exposing them to glutamate.

Immediately after this, the receptors were flash frozen and analyzed with cryoEM to get a snapshot of the AMPA receptors bound to the major signaling molecule, glutamate.

After assembling more than a million images taken with cryoEM, the team found that glutamate molecules act like a key that unlocks the door to the channel, enabling it to open more widely. This occurs by the clamshell-like structure of the AMPA receptor closing around glutamate, an action that pulls open the channel below.

Twomey’s previous research has shown that drugs such as perampanel, used to treat epilepsy, act as a door stopper around the AMPA receptor to limit the channel from opening and reducing the abundance of activity known to happen in brain cells of people with epilepsy.

Twomey says the findings could be used to develop new drugs that bind to AMPA receptors in different ways that either open or close the signaling channels of brain cells.

“With each new finding, we are figuring out each of the building blocks that enable our brains to function,” says Twomey.


Its landing place on neurons is a channel called an AMPA receptor, which interacts with glutamate, and then acts like a pore that takes in charged particles. Credit: Neuroscience News

Take your pick of which molecule it is as AI/Wikipedia are internally conflicted AND Glutamate.

Credits: ChatGPT:

« Last Edit: April 06, 2025, 07:03:37 AM by Chip »
friendly
0
funny
0
informative
0
agree
0
disagree
0
like
0
dislike
0
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
measure twice, cut once

Tags:
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
72 Views
Last post March 30, 2015, 05:48:16 PM
by andrew
0 Replies
13134 Views
Last post April 27, 2015, 02:43:51 AM
by smfadmin
10 Replies
12274 Views
Last post October 20, 2015, 01:20:05 PM
by Chip
0 Replies
9589 Views
Last post October 20, 2019, 04:25:17 AM
by Chip
0 Replies
9381 Views
Last post December 16, 2019, 07:21:58 AM
by Chip
0 Replies
11168 Views
Last post February 04, 2024, 07:02:28 AM
by Chip
0 Replies
1562 Views
Last post February 14, 2025, 04:15:44 AM
by smfadmin
2 Replies
1830 Views
Last post March 04, 2025, 07:19:35 AM
by Chip
0 Replies
801 Views
Last post March 22, 2025, 09:18:15 AM
by smfadmin
0 Replies
569 Views
Last post April 05, 2025, 04:46:38 PM
by smfadmin


dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse





TERMS AND CONDITIONS

In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE


Founded December 2014
SimplePortal 2.3.6 © 2008-2014, SimplePortal